HGV Investor Overview M A R C H 2 0 2 6 Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements convey management's expectations as to the future of HGV, and are based on management's beliefs, expectations, assumptions and such plans, estimates, projections and other information available to management at the time ...

Q1 2026 Supplemental Information Progress Financial Results March 30, 2026 Forward Looking Statements This presentation contains statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Progress has identified some of these forward-looking statements with words like "believe," "may," "could," "would," "might," "should," "expect," "intend," "plan," "target," "anticipate" an ...

Fourth Quarter and Full Year 2025 Earnings March 30, 2026 Disclaimer The material that follows is a presentation ("Presentation") of information about Innventure, Inc. and its subsidiaries (together referred to herein as "Innventure," the "Company," "us," "our," or "we") as of the date of this presentation. The Presentation does not purport to contain all information that may be required or desired by a party interested in investigating the Company, its business or prospects, and it shall not be deemed to b ...

The Company's financial results for the fiscal quarter and fiscal year ended January 31, 2026 reflect inclusion of the business operations of AccessOne from November 12, 2025. The post-acquisition results reflect only a partial period and include integration-related costs and therefore are not indicative of AccessOne's full-quarter or full-year performance. Investor Presentation FOURTH QUARTER | FISCAL YEAR 2026 Disclaimer This presentation includes express or implied statements that are not historical fact ...

Delivering the Future of Genomic Medicines March 30, 2026 Forward-Looking Statements and Legal Disclaimers This presentation, and accompanying oral commentary, contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential and value of our product candidates and engineered capsids, including the ability of our zinc finger epigenetic regulators to address various neurologica ...

March 30th, 2026 4:30 PM Eastern Time Fourth Quarter & Year-end 2025 Operating & Financial Results Conference Call / Webinar NASDAQ :LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potenti ...

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure for the demand for SOL, or activity on the SOL network, to continue to develop and grow as predicted in our DFDV Model or at all; (iii) volatility in our ...

Q4 / FY 2025 Earnings Call March 30, 2026 © 2024 – 2026 Bicara Therapeutics Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding our strategy, business plans and focus; express or implied statements regarding the clinical development of ficerafusp alfa, including anticipated substantial enrollm ...

LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO Disclaimer Q4 2025 Business Update March 30, 2026 Nasdaq: PAVM 2 ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the "Companies") that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors that might cause or contribute to such differences include, but are not limited to, ...

March 30, 2026 Sysco to Acquire Restaurant Depot to Expand into High- Margin, Growing and Resilient Cash & Carry Channel FORWARD-LOOKING STATEMENTS This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "seeks," "aims," "plans," ...